{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:57:39Z","timestamp":1776448659875,"version":"3.51.2"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.therap.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T09:14:32Z","timestamp":1742894072000},"page":"673-680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Usefulness of thiopurines therapeutic drug monitoring in patients with inflammatory bowel disease"],"prefix":"10.1016","volume":"80","author":[{"given":"Zohra","family":"Chadli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6380-9339","authenticated-orcid":false,"given":"Ibtissem","family":"Hannachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Ben Fredj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hichem","family":"Loghmari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifa","family":"Ben Romdhane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahlem","family":"Slama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amel","family":"Chaabane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Safer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Aouam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2025.03.001_bib0140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/1756283X10376121","article-title":"Optimizing therapy with 6-mercaptopurine and azathioprine: to measure or not to measure?","volume":"3","author":"Deshpande","year":"2010","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.therap.2025.03.001_bib0145","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/bcp.12226","article-title":"Implementation of TPMT testing","volume":"77","author":"Lennard","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2025.03.001_bib0150","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00228-008-0478-6","article-title":"Clinical pharmacology and pharmacogenetics of thiopurines","volume":"64","author":"Sahasranaman","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2025.03.001_bib0155","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.3748\/wjg.v17.i37.4166","article-title":"Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease","volume":"17","author":"Bradford","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.therap.2025.03.001_bib0160","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0378-4347(87)80340-7","article-title":"Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells","volume":"423","author":"Lennard","year":"1987","journal-title":"J Chromatogr"},{"key":"10.1016\/j.therap.2025.03.001_bib0165","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/039463201202500213","article-title":"A validated HPLC method for the monitoring of thiopurine metabolites in whole blood in paediatric patients with inflammatory bowel disease","volume":"25","author":"Cangemi","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.therap.2025.03.001_bib0170","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/gut.48.5.642","article-title":"Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease","volume":"48","author":"Cuffari","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.therap.2025.03.001_bib0175","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jpba.2008.10.045","article-title":"Development and validation of an HPLC method for the rapid and simultaneous determination of 6-mercaptopurine and four of its metabolites in plasma and red blood cells","volume":"49","author":"Hawwa","year":"2009","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.therap.2025.03.001_bib0180","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/gut.49.5.665","article-title":"Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease","volume":"49","author":"Lowry","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.therap.2025.03.001_bib0185","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1590\/S0100-879X2004000500004","article-title":"An improved HPLC method for the quantitation of 6-mercaptopurine and its metabolites in red blood cells","volume":"37","author":"Oliveira","year":"2004","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.therap.2025.03.001_bib0190","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/ibd.21458","article-title":"Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease","volume":"17","author":"Haines","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.therap.2025.03.001_bib0195","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1111\/bcp.15315","article-title":"Therapeutic drug monitoring of thiopurines: effect of reduced 6-thioguanine nucleotide target levels in inflammatory bowel disease patients","volume":"88","author":"Boekema","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2025.03.001_bib0200","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.anpedi.2019.10.005","article-title":"Laboratory determination of thiopurine levels in paediatric patients with inflammatory bowel disease","volume":"93","author":"Mart\u00edn-Masot","year":"2020","journal-title":"An Pediatr (Engl Ed)"},{"key":"10.1016\/j.therap.2025.03.001_bib0205","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/jcag\/gwaa005","article-title":"Real-world use of azathioprine metabolites changes clinical management of inflammatory bowel disease","volume":"4","author":"Wilson","year":"2021","journal-title":"J Can Assoc Gastroenterol"},{"key":"10.1016\/j.therap.2025.03.001_bib0210","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1053\/j.gastro.2006.01.046","article-title":"Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis","volume":"130","author":"Osterman","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.therap.2025.03.001_bib0215","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/ecco-jcc\/jjx089","article-title":"A systematic review and meta-analysis of 6-thioguanine nucleotide levels and clinical remission in inflammatory bowel disease","volume":"11","author":"Estevinho","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.therap.2025.03.001_bib0220","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0016-5085(00)70140-5","article-title":"Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease","volume":"118","author":"Dubinsky","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.therap.2025.03.001_bib0225","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00044011-200424080-00006","article-title":"Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy","volume":"24","author":"Gilissen","year":"2004","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.therap.2025.03.001_bib0230","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/FTD.0b013e318282c3a6","article-title":"Relationship between azathioprine dosage and thiopurine metabolites in pediatric ibd patients: Identification of covariables using multilevel analysis","volume":"35","author":"Nguyen","year":"2013","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.therap.2025.03.001_bib0235","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/MIB.0000000000000347","article-title":"Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine","volume":"21","author":"Lee","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.therap.2025.03.001_bib0240","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jgh3.12004","article-title":"Thiopurine metabolite level and toxicity in Indians with inflammatory bowel disease","volume":"1","author":"Parkar","year":"2017","journal-title":"JGH Open"},{"key":"10.1016\/j.therap.2025.03.001_bib0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/lupus-2023-001036","article-title":"Azathioprine metabolite levels and outcomes during pregnancies with rheumatic disease","volume":"11","author":"Balevic","year":"2024","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.therap.2025.03.001_bib0250","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1365-2036.2011.04848.x","article-title":"Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine","volume":"34","author":"Armstrong","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.therap.2025.03.001_bib0255","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10620-021-06836-3","article-title":"Adverse events of thiopurine therapy in pediatric inflammatory bowel disease and correlations with metabolites: a cohort study","volume":"67","author":"Jagt","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.therap.2025.03.001_bib0260","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/FTD.0000000000000414","article-title":"Pharmacology of thiopurine therapy in inflammatory bowel disease and complete blood cell count outcomes: a 5-year database study","volume":"39","author":"Meijer","year":"2017","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.therap.2025.03.001_bib0265","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00054725-200307000-00004","article-title":"Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine","volume":"9","author":"Thomas","year":"2003","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.therap.2025.03.001_bib0270","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1007\/s10620-022-07719-x","article-title":"Low-dose azathioprine in combination with allopurinol: the past, present and future of this useful duo","volume":"67","author":"Turbayne","year":"2022","journal-title":"Dig Dis Sci"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725000551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595725000551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:21:15Z","timestamp":1776446475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595725000551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0040595725000551"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2025.03.001","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Usefulness of thiopurines therapeutic drug monitoring in patients with inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}